Sosei Co., Ltd.

43 articles about Sosei Co., Ltd.

• Novartis AG, Sosei Co., Ltd. COPD Drug Phase III Trial Meets Primary Endpoint

  4/19/2011

• Sosei Co., Ltd. Agrees Terms With ASKA Pharmaceutical for Commercialization of SOH-075 (NorLevo(R))

  10/22/2008

• Sosei Co., Ltd. Announces Outcome of Strategy Review

  5/14/2008

• Sosei Co., Ltd. Announces Start of AD 923 Phase III Studies in Europe

  2/12/2008

• Sosei Co., Ltd. and Vectura Group plc Announce Start of Phase II Studies of QVA149 for the Treatment of COPD

  11/15/2007

• Sosei Co., Ltd. Announces Start of SD118 Phase I Studies

  5/29/2007

• Sosei Co., Ltd. Announces New Appointments to its Board of Directors

  5/25/2007

• Sosei Group Corporation Release: AD 923 Commences Phase 1 Clinical Development in the USA

  3/5/2007

• Sosei Co., Ltd. Announces New Fundraising

  1/5/2007

• Sosei Announces That QVA149 Clinical Development Starts In 2007 And Updates The Status Of NVA237

  11/29/2006

• Sosei Inc. Announces Initiation Of Phase I Trial For Emergency Contraceptive Pill NorLevo(R)

  11/17/2006

• Sosei Co., Ltd. And Vectura Group plc Announce Successful Completion Of Phase IIb Trial Of NVA237 For COPD

  6/28/2006

• Sosei Co., Ltd. Announces Agreement With Mundipharma International Limited For Ad 923

  6/27/2006

• Sosei Co., Ltd. Business Strategy Update And Portfolio Review; Headcount Reduction

  6/22/2006

• Sosei Co., Ltd.: Consolidated Financial Results For The Fiscal Year Ended March 31, 2006

  5/15/2006

• Sosei Co., Ltd. Discontinues Development Of SOU-001

  5/15/2006

• Sosei Co., Ltd. Announces Reorganization Of Its Corporate Structure Under Holding Company

  5/15/2006

• Sosei Co., Ltd. Announces Company Name Change Of Two Affiliates

  5/15/2006

• PsychoGenics Inc. And Sosei Co., Ltd. Partner To Identify New CNS Therapies

  4/10/2006

• Sosei Co., Ltd. Announces New Appointments; Yoshiyuki Yamakawa New Representative Executive Officer, Executive Vice President And CFO, Head Of Japanese Operations

  3/30/2006